

2. Data Abstraction Tool for Observational Studies

I. Article information

1. What is the name of this study? (e.g. DART, Physician's Health Study) *Omit if name of study is not provided.*

- DART
- Physician's Health Study
- Maastricht Essential Fatty Acid Birth (MEFAB) Cohort
- The DIAMOND Study (DHA Intake And Measurement Of Neural Development)
- data using DIAMOND study
- POSGRAD
- NUHEAL
- Infant Fish Oil Supplementation Study (IFOS)
- Danish National Birth Cohort
- Groningen LCPUFA study
- DINO (Docosahexaenoic acid for the Improvement in Neurodevelopmental Outcome)
- DOMINO
- INFAT
- BeMIM (Belgrade-Munch Infant Milk Trial)
- GINI
- The Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO)
- Childhood Asthma Prevention Study
- Salmon in Pregnancy Study (SiPS)
- Project Viva
- INMA
- Avon Longitudinal Study of Parents and Children (ALSPAC)

- Alberta Pregnancy Outcomes and Nutrition (APrON) study
- Osaka maternal and child health study
- Amsterdam Born Children and their Development (ABCD)
- EDEN
- LISApplus
- The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study
- KOALA Birth Cohort Study
- Finnish Type 1 Diabetes Prediction and Prevention Nutrition Study
- The Prevention of Allergy among Children in Trondheim study
- Norwegian Mother and Child Cohort Study (MoBa)
- Infancia y Medio Ambiente (INMA) Project
- Pregnancy, Infection and Nutrition Study
- Nurses Health Study
- Kyushu Okinawa Maternal and Child Health Study
- Southampton Women's Survey

[Other study names](#)

2. Study Design

- Trial: Randomized Parallel (Omega-3 vs. Control; Omega-3 XX vs. X)
- Trial: Randomized Cross-over
- Trial: Randomized Factorial Design
- Observational: Prospective, longitudinal, comparative study
- Observational: Nested Case Control

[Other](#)

[Clear Response](#)

3. Funding source

- Industry funded

- Government funded
- Some authors employed by industry (companies that make the supplements)
- Funding or affiliations not reported
- Multiple foundations and Societies
- None of the authors had any personal or financial conflicts of interest
- Trade group funded
- March of Dimes
- Manufacturer supplied product
- Some authors serve on scientific advisory boards for corporations
- Alberta Innovates-Health Solutions
- Infant formula manufacturer performed assays

Other funding source

4. Country in which study conducted (where subjects live) *Note that this might be different than the countries where the authors are based. Select "NR (not reported)" if it's truly unclear.*

- US
- Canada
- Denmark
- Finland
- Germany
- Greece
- Italy
- Japan
- Netherlands
- Norway
- Sweden

- UK
- NR (not reported)
- Mexico
- Australia
- Taiwan
- Spain
- Hungary
- Turkey
- Bangladesh
- Thailand
- Serbia
- Multie-center study in hospitals of 11 countries in Europe
- Iceland
- England
- France
- Malaysia
- India

[Other](#)

5. Study Population

- Healthy infants or children
- Preterm infants
- Healthy pregnant women
- Postpartum women
- Breast-feeding women

- Low birth weight infants
- Pregnant mothers with allergies and their offspring
- Pregnant women whose unborn children were at high risk of developing asthma
- children with family history of allergy
- Children with allergies
- Infants at risk for Diabetes 1
- Pregnant mothers without allergies and their offspring
- Children with a family history of asthma

Other

6. Inclusion criteria as defined in study

7. Exclusion criteria

II. Participant Information

1. Sample size

Pregnant	Lactating mothers	Mothers	Infants
<input type="checkbox"/> # Enrolled/Rand omized	<input type="checkbox"/> # Enrolled/Rand omized	<input type="checkbox"/> # Enrolled/Rand omized	<input type="checkbox"/> # Enrolled/Rand omized
<input type="checkbox"/> # of withdrawals	<input type="checkbox"/> # of withdrawals	<input type="checkbox"/> # of withdrawals	<input type="checkbox"/> # of withdrawals
<input type="checkbox"/> # of completers (largest follow- up)	<input type="checkbox"/> # of completers (largest follow- up)	<input type="checkbox"/> # of completers (largest follow- up)	<input type="checkbox"/> # of completers (largest follow- up)

2. Age at baseline

Mean age (Pregnant)	Mean age (Lactating mothers)	Mean age (Mothers)	Mean age (Infants)
----------------------------	-------------------------------------	---------------------------	---------------------------

Standard Deviation (Pregnant)	Standard Deviation (Lactating mothers)	Standard Deviation (Mothers)	Standard Deviation (Infants)
Age range (Pregnant)	Age range (Lactating mothers)	Age range (Mothers)	Age range (infants)

3. Race/Ethnicity (Mother)

- White/European (specify %)
- Black/African American/etc. (specify %)
- Asian (specify %)
- Hispanic (specify %)
- Inuit/Eskimo (specify %)
- NR (specify %)
- varied by study site and experimental group (specify %)
- Minority (specify %)
- Other
- non black
- Puerto Rican/Latino
- Native Hawaiian or other pacific ethnicity
- non-western

Other

4. Race/Ethnicity (Infant)

- White/European (specify %)
- Black/African American/etc. (specify %)
- Asian (specify %)
- Hispanic (specify %)
- Inuit/Eskimo (specify %)
- Not reported (specify %)
- varied by study site and experimental groups (specify %)
- Non-white
- Not relevant

Other

5. Is baseline biomarker information reported?


Yes No [Clear Response](#)

6. Is baseline Omega-3 intake reported?


Yes No [Clear Response](#)

7. Dates of study


When was the actual study conducted as opposed to when it was published



8. Medical history



9. Risk Type



10. Exposure Timing

e.g., second and third trimester, birth to age 1..

